Table 3 Treatment outcome by sarcopenia status.

From: Impact of sarcopenia in patients with advanced non–small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study

 

No sarcopenia (n = 20)

Sarcopenia (n = 22)

p-value

Number of doses, median (range)

11 (1–44)

3.5 (1–26)

0.021

Response rate (95% CI)

40.0% (19.1–63.9%)

9.1% (1.1–29.2%)

0.025

Disease control rate (95% CI)

65.0% (40.8–84.6%)

34.8% (17.2–59.3%)

0.12

1-year PFS (95% CI)

38.1% (21.3–68.1%)

10.1% (2.7–37.3%)

—

  1. Abbreviations: CI, confidence interval; PFS, progression-free survival.
Back to article page